IP Library Granted Patent US 7,241,873
Granted Patent B2
US 7,241,873 · App. 10/489,866 · Granted Jul 10, 2007

Recombinant anti-osteopontin antibody and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,241,873
App. No.
10/489,866
Granted
Jul 10, 2007
Kind
B2
Abstract

A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.

Claims (13)

1. A chimeric anti-osteopontin antibody, which inhibits the binding between a thrombin-cleaved N-terminal fragment of osteopontin and:

an integrin recognizing the site of amino acid sequence RGD, and

an integrin recognizing the site of amino acid sequence SVVYGLR (residues 11–17 of SEQ ID NO: 1);

wherein said antibody has a heavy chain variable region having an amino acid sequence of SEQ ID NO: 19 and light chain variable region having an amino acid sequence of SEQ ID NO: 20.

2. The chimeric anti-osteopontin antibody according to claim 1 , wherein the heavy chain constant region in the antibody is human Igγ1.

3. The chimeric anti-osteopontin antibody according to claim 1 , wherein the light chain constant region in the antibody is human Igκ.

4. A humanized anti-osteopontin antibody, wherein said antibody inhibits the binding between a thrombin-cleaved N-terminal fragment of osteopontin and:

an integrin recognizing the site of amino acid sequence RGD, and

an integrin recognizing the site of amino acid sequence SVVYGLR (residues 11–17 of SEQ ID NO: 1);

wherein said antibody has heavy chain CDR1, CDR2 and CDR3 having an amino acid sequence of SEQ ID NOS: 21, 22 and 23 respectively, and light chain CDR1, CDR2 and CDR3 having an amino acid sequence of SEQ ID NOS: 24, 25 and 26 respectively.

5. The humanized anti-osteopontin antibody according to claim 4 , wherein said antibody has heavy chain variable region having an amino acid sequence of SEQ ID NO: 28 and light chain variable region having an amino acid sequence of SEQ ID NO: 30.

6. The humanized anti-osteopontin antibody according to claim 4 , wherein the heavy chain constant region in the antibody is human Igγ1.

7. The humanized anti-osteopontin antibody according to claim 4 , wherein the light chain constant region in the antibody is human Igκ.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2006
From: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 018234/0077 →
MERGER Recorded Dec 12, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 017073/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2004
From: UEDE, TOSHIMITSU; KON, SHIGEYUKI; YAMAMOTO, NOBUCHIKA; HIGUCHI, HIROFUMI; TORIKAI, MASAHARU; TOKIEDA, YOSHIYUKI; NAKASHIMA, TOSHIHIRO; MAEDA, HIROAKI
To: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.; FUJISAWA PHARMACEUTICAL CO., LTD.
Reel/Frame 015298/0654 →